Notably, CD49d-positive CLL patients experience reduced LN shrinkage and lymphocytosis, and the degree of CD49d positivity correlates with an inferior response to BTKis, such as ibrutinib and acalabrutinib [194,195]. This evidence concerns the gene ITGA4 and B-cell chronic lymphocytic leukemia.